Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.

Antiviral therapy - 1 Feb 2004

Corzillius Michael, Mühlberger Nikolai, Sroczynski Gaby, Jaeger Hans, Wasem Jürgen, Siebert Uwe

Abstract excerpt

OBJECTIVES: Single use of genotypic antiretroviral resistance testing (GART) after first failure of highly active antiretroviral therapy (HAART) was reported to be cost effective; its use prior HAART initiation is unknown. Guidelines recommend GART after each treatment failure. We assessed the cost effectiveness of GART used routinely after first and subsequent treatment failures. Furthermore, we determined the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiretroviral Therapy, Highly Active

Share to Cost-Benefit Analysis

Share to Germany

Share to Life Expectancy

Share to Markov Chains

Source

Identifiers

PMID: 15040534

Genes

GART

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.PMID 15040534Read ↗

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.Semantic proximity Read ↗

Cost-effectiveness analysis of using antiretroviral drug resistance testing.Semantic proximity Read ↗

A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?Semantic proximity Read ↗

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.Semantic proximity Read ↗

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Semantic proximity Read ↗

The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.Semantic proximity Read ↗

Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited setting.Semantic proximity Read ↗

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income SettingsSemantic proximity Read ↗

Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.Semantic proximity Read ↗

[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].Semantic proximity Read ↗

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.Semantic proximity Read ↗

The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.